Viridian Therapeutics, Inc. (NASDAQ: VRDN)
$22.2100
+0.0400 ( +0.18% ) 126.0K
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Market Data
Open
$22.2100
Previous close
$22.1700
Volume
126.0K
Market cap
$1.69B
Day range
$21.6660 - $22.3850
52 week range
$11.4000 - $25.3850
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 2 | Jun 28, 2024 |
| 4 | Insider transactions | 2 | Jun 28, 2024 |
| 4 | Insider transactions | 2 | Jun 28, 2024 |
| 8-k | 8K-related | 15 | Jun 20, 2024 |
| 10-q | Quarterly Reports | 70 | May 08, 2024 |
| 8-k | 8K-related | 16 | May 08, 2024 |
| ars | Annual reports | 1 | Apr 26, 2024 |
| def | Proxies and info statements | 5 | Apr 26, 2024 |
| 8-k | 8K-related | 14 | Apr 16, 2024 |
| 4 | Insider transactions | 1 | Apr 01, 2024 |